Christian Grommes, MD

Dr. Chieh-Lung Cheng reports a gastrointestinal bleeding event in one patient that resolved with dose reduction, allowing continued therapy.

Dr. Lakshmi Nayak turns to the future role of BTK inhibitors in frontline and maintenance therapy.

Dr. Chieh-Lung Cheng describes his practical monitoring approach in Taiwan, where tirabrutinib is the only BTK inhibitor approved for relapsed/refractory PCNSL.

Dr. Lakshmi Nayak asks Dr. Motoo Nagane about real-world patient selection and dose maintenance in Japan, drawing on several years of post-approval experience.

Dr. Chieh-Lung Cheng addresses where BTK inhibitors fit in relapsed/refractory PCNSL and how he selects patients, noting that in Taiwan tirabrutinib is used as monotherapy rather than in combination.

Dr. Lakshmi Nayak asks Dr. Motoo Nagane, as a neurosurgeon and neuro-oncologist, about the pharmacologic importance of CNS penetration.

Dr. Christian Grommes revisits the early ibrutinib experience, when nearly every B-cell malignancy appeared responsive to BTK inhibition, and recalls the setback in non-CNS diffuse large B-cell lymphoma, where responses and progression-free survival were disappointing.

Dr. Lakshmi Nayak transitions the discussion to the evolution of the BTK inhibitor class, the program's second module.

Dr. Motoo Nagane discusses the evolving treatment pathway for primary CNS lymphoma (PCNSL) in Japan following the approval of tirabrutinib for relapsed or refractory disease.

Dr. Chieh-Lung Cheng describes the impact of tirabrutinib availability on the management of relapsed/refractory primary CNS lymphoma (PCNSL) in Taiwan.

Dr. Christian Grommes discusses the emerging role of BTK inhibitors in relapsed/refractory primary CNS lymphoma (PCNSL), focusing on U.S. off-label use and ongoing clinical investigation.

Experts unpack BTK inhibitor use for relapsed primary CNS lymphoma, sharing Japan and Taiwan real‑world data, trials, and tirabrutinib insights.

Experts debate BTK inhibitors for primary CNS lymphoma, sharing trial and real-world insights on tirabrutinib and options for relapsed disease.

Christian Grommes, MD, discusses how BTK inhibitors and CAR T-cell therapy fit into the relapsed/refractory primary CNS lymphoma treatment paradigm.

Christian Grommes, MD, shares results from a phase 2 study evaluating ibrutinib plus rituximab, methotrexate, vincristine, and procarbazine in PSNCL.